Advertisement
NEW YORK, Fev. 7, 2018 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p04940093
SummaryHematological cancer describes a group of malignancies that affect the blood, lymph nodes and bone marrow. The three main types are leukemia, lymphoma and myeloma. The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma together. Although individually accounting for relatively modest proportions of new cancer cases, when combined these hematological cancers are estimated to be the third most common type of cancer in the US. Furthermore, there are predicted to be over 58,000 deaths caused by hematological cancers in the US in 2017 (ACS, 2017).Hematological cancers therapy area is relatively large, and is characterized by malignancies of the blood - specifically a proliferation of abnormal white blood cells, which subsequently has downstream effects on other blood and immune cells. There are three main types of hematological cancer: leukemia; lymphoma and myeloma. Leukemia is caused by a proliferation of abnormal white blood cells that impair the ability of the bone marrow to produce red blood cells and platelets. Lymphoma affects the lymphocytes of the lymphatic system, which collect in lymph nodes and other tissue and impair the immune system. Myeloma affects plasma cells and prevents the normal production of antibodies.Hematological cancers pipeline is the largest within the oncology therapy area - with 1,474 programs in active development it accounts for over 19% of the therapy area. There are a total of 477 first-in-class pipeline programs in development for hematological cancers, representing 40% of those with a disclosed molecular target. Cytokine signaling targets make up the greatest proportion of pipeline and first-in-class programs, followed in both instances by kinases. These two target categories are intrinsically linked with components of immune response, and are responsible for the majority of targets in part due to the nature of hematological cancers and their action on immune cells. Additionally, much of the most promising potential within the hematological cancers area revolves around targeted immunotherapies.Between 2006 and the beginning of 2017 a total of 467 licensing deals and 323 co-development deals were completed in the hematological cancers therapy area. Of those with a disclosed value, the combined aggregate deal value was $67.6 billion, highlighting that strategic consolidations within hematological cancers are particularly valuable. The high level of deal-making activity is also indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations in order to mitigate some of the risks and the significant failure rates associated with drug development in the hematological cancers therapy area. Companies have a meaningful incentive to invest in pipeline programs due to the strong commercial performance of leading cancer products.The report "Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline" assesses versatile and first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 477 first-in-class products.In depth, this report provides the following -- Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.- Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.- Helps to understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.- Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.Scope- With 1,474 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future hematological cancer market?- There are 477 first-in-class products in the hematological cancer pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?- The majority of first-in-class products were identified to be in development for multiple indications. Are versatile products likely to play a key role in the future treatment of hematological cancer?- Analysis of the history of strategic consolidations revealed an increasing amount of deal activity and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?Reasons to buy- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.- Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.- Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.- Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are being developed for.- Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.Read the full report: https://www.reportlinker.com/p04940093
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/frontier-pharma-first-in-class-innovation-in-hematological-cancers---cytokine-signaling-and-kinase-targeted-immunotherapies-dominate-a-large-and-highly-versatile-pipeline-300595035.html
SOURCE Reportlinker
